Pendar Technologies LLC

Pendar Technologies LLC, a small business manufacturer of spectroscopy-based chemical detection and identification instruments, operates as a prime contractor (92% of recent awards) and subcontractor on federal research, procurement, and grant programs. The Cambridge, Massachusetts-based limited liability company competes predominantly under total small business set-asides across SBIR/STTR and procurement vehicles, with core capabilities in portable Raman spectrometers, quantum cascade lasers, and mid-infrared sensor platforms for counterterrorism, counternarcotics, and materials analysis missions.

Pendar's customer concentration skews heavily toward security and defense agencies. The top five funding agencies account for 89% of combined potential value, anchored by the Department of Homeland Security Transportation Security Administration ($67.3 million across 2 awards) and DHS Science and Technology Directorate ($13.3 million across 6 awards). The Navy Naval Air Systems Command places the most orders by count (14 awards, $6.2 million combined potential value), followed by NASA Shared Services Center (7 awards, $2.7 million) and Naval Sea Systems Command (6 awards, $3.7 million). The ranking split between volume and dollars reflects Pendar's dual posture: high-volume SBIR Phase I work with NASA and Navy (smaller per-award ceilings) and large single-customer procurement with TSA for Chemical Analysis Device systems.

Pendar holds a $35 million single-award indefinite delivery contract with TSA for CAD units, software upgrades, and maintenance running through September 2029, awarded September 25, 2024. On September 26, 2024, TSA exercised Option Year 2 against this IDIQ with a $32.3 million firm fixed-price delivery order for CAD unit procurement, representing the vendor's largest recent transaction. Pendar also operates on the GSA Multiple Award Schedule, where 13 task orders totaling $1.2 million have been placed by DHS Immigration and Customs Enforcement, Department of Justice Bureau of Alcohol, Tobacco, Firearms and Explosives, and other agencies for handheld Raman spectrometers and field lab accessories. Recent prime work includes a $8.8 million Army procurement of 120 Commercial Proximate Chemical Agent Detector systems (June 2026, total small business set-aside), a $1.497 million DHS SBIR Phase II contract on fentanyl attribution forensics (September 2026, cost-plus-fixed-fee, completion March 2029), and a $999,129 DHS SBIR Phase II contract supporting CBP and ICE counternarcotics missions (April 2025, cost-plus-fixed-fee, completion March 2027).

Activity has grown from five awards in 2022 to thirteen in 2024, with seven awards (combined potential value $14.8 million) reaching ultimate completion inside the next twenty-four months and facing recompete exposure. The vendor's capability portfolio centers on R&D in physical and engineering sciences (35 awards) and analytical laboratory instrument manufacturing (23 awards), with secondary focus on quantum cascade laser development, mid-infrared sensor miniaturization, and integrated optics for chemical sensing. SBIR and STTR constitute the dominant mechanism — Phase I awards predominate in 2022–2023, with Phase II scaling in 2024–2025 — suggesting Pendar uses SBIR as a pipeline to technology maturation and procurement follow-on.

On subcontracting, Pendar operates as a prime in 92% of recent awards and self-performs work on SCI-reportable federal service contracts. SCI-reported invoicing reached $1.9 million in FY2025 across 2.8 FTEs, up from $1.8 million in FY2024 across 2.2 FTEs; median government-paid hourly rates on federal service contracts run around $427/hr, with senior labor pricing through $682/hr. The vendor names Battelle Memorial Institute, Teledyne Scientific & Imaging, and Atlantic Diving Supply as subcontracting primes, delivering chemical and biological sensor development, quantum cascade laser and interband cascade laser source work on DARPA projects, and integration of Pendar detection systems into protective equipment platforms. A single sub-grant with The General Hospital Corporation centers on resonance Raman spectroscopy for tissue oxygenation monitoring in critically ill neonates (NIH National Institute of Child Health and Human Development, September 2024 through August 2025).